Home » Posts tagged with » Pfizer
JAVELIN Medley trial : First patient dosed with BAVENCIO, CMP-001 combo

JAVELIN Medley trial : First patient dosed with BAVENCIO, CMP-001 combo

Checkmate Pharmaceuticals announced the dosing of the first patient in a phase 1b/2 study of BAVENCIO (avelumab) in multi-drug combinations with its lead candidate CMP-001 in patients having squamous cell cancer of the head and neck (SCCHN), as part of the JAVELIN Medley trial. CMP‐001 is a C0pG‐A Toll‐like receptor 9 (TLR9) agonist that is […]

RESET clinical trial results : Rivipansel flops in phase 3 trial in SCD

RESET clinical trial results : US pharma giant Pfizer’s rivipansel failed to meet the primary and key secondary efficacy endpoints of a phase 3 trial called RESET in sickle cell disease (SCD). The aim of the RESET clinical trial was to assess the efficacy and safety of rivipansel in sickle cell disease patients, aged six […]

Continue reading …
Mylan Upjohn merger : Pfizer to merge off-patent drugs unit with Mylan

Mylan Upjohn merger : US pharma giant Pfizer will spin off Upjohn, its off-patent branded and generic established medicines business, and merge it with Dutch pharma company Mylan, to form a new global pharma company. As per the terms of the all-stock, Reverse Morris Trust transaction, each of Mylan shares will be converted into one […]

Continue reading …
Pfizer wraps up $810m acquisition of Swiss biotech company Therachon

Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech company Therachon, which is focused on rare diseases, in a deal worth up to $810 million, as per the latest pharma acquisition news. The clinical-stage Therachon is currently engaged in developing treatment of achondroplasia and short bowel […]

Continue reading …
Pfizer opens $200m biologics clinical manufacturing facility in Andover, MA

US pharma giant Pfizer has opened Andover Clinical Manufacturing Facility (ACMF), a new 175,000sft biologics clinical manufacturing facility built with an investment of over $200 million in Andover, Massachusetts. The biologics clinical manufacturing facility will be used for the development and production of complex biologics and vaccines and is expected to expand Pfizer’s BioTherapeutics Pharmaceutical […]

Continue reading …
Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover the treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. Latest Ibrance FDA approval Under the new indication approved […]

Continue reading …
Pfizer lung cancer drug Vizimpro bags CHMP’s positive opinion

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pfizer lung cancer drug Vizimpro (dacomitinib) 45 mg in Europe as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The positive opinion adopted by the European Medicines Agency (EMA) committee is […]

Continue reading …
Pfizer, AbbVie resolve IP matters for adalimumab biosimilar

Pfizer adalimumab biosimilar update : Pfizer and AbbVie have signed licensing agreements to resolve all global intellectual property (IP) matters pertaining to the former’s proposed biosimilar of the latter’s rheumatoid arthritis drug Humira (adalimumab). Pfizer adalimumab biosimilar update As per the agreement terms, Pfizer has secured a non-exclusive patent license from AbbVie for the use […]

Continue reading …
Pfizer lung cancer drug Lorbrena bags US FDA approval

Lorbrena FDA approval : US pharma giant Pfizer has bagged approval from the US Food and Drug Administration (FDA) for Lorbrena (lorlatinib) for anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC). Lorbrena FDA Approval The FDA approval of Lorbrena is for the ALK-positive NSCLC patient population whose condition has progressed on treatment […]

Continue reading …
Pfizer DMD drug domagrozumab fails in two clinical trials

Pfizer DMD drug update : US pharma giant Pfizer will scrap a couple of ongoing clinical trials evaluating its humanized monoclonal antibody domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD) owing to negative results. The two trials of the Pfizer DMD drug are B5161002 – a phase 2 safety and efficacy study and […]

Continue reading …
Page 1 of 212